GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Short-Term Debt

Neurogene (Neurogene) Short-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Short-Term Debt?

Neurogene's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.


Neurogene Short-Term Debt Historical Data

The historical data trend for Neurogene's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Short-Term Debt Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
- - -

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial - - - - -

Neurogene Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Neurogene Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Neurogene's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurogene (Neurogene) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines